ADVENTRX Pharmaceuticals to Present at the BIO Investor Forum on October 29
More News related to ANX
- ADVENTRX Pharmaceuticals Reports Third Quarter Financial Results
- Trading Review for Adventrx Pharmaceuticals Inc. Issued by Beacon Equity
- ADVENTRX Pharmaceuticals to Present at the BIO Investor Forum on October 29
- Adventrx (ANX) Comments on Recent Financial Activity, AMEX Listing, and Denner Resignation
- ADVENTRX Provides Business Update Following Recent Financing Activity
More News related to ANX
- ADVENTRX Pharmaceuticals Reports Third Quarter Financial Results
- Trading Review for Adventrx Pharmaceuticals Inc. Issued by Beacon Equity
- ADVENTRX Pharmaceuticals to Present at the BIO Investor Forum on October 29
- Adventrx (ANX) Comments on Recent Financial Activity, AMEX Listing, and Denner Resignation
- ADVENTRX Provides Business Update Following Recent Financing Activity
More News related to Press Releases
- Wunderlich Securities Downgrades Gran Tierra Energy (GTE) to Hold
- Stephens Downgrades Benihana (BNHN) to Equalweight
- UBS Downgrades NRG Energy (NRG) to Neutral; Cuts Target to $26
- Citi Cuts Lukoil (LUKOY) to Hold
SAN DIEGO, Oct. 22 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company's Principal Executive Officer, Brian M. Culley, will present at the 8th Annual BIO Investor Forum on Thursday, October 29, 2009, at 8:30 a.m. Pacific time, in the Sea Cliff room at the Palace Hotel in San Francisco.
Interested parties can access a live audio webcast and slide presentation on the ADVENTRX Pharmaceuticals Web site at www.adventrx.com. An archived presentation will be available on the Web site for 30 days.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the safety of existing cancer treatments. More information can be found on the Company's web site at www.adventrx.com.
SOURCE ADVENTRX Pharmaceuticals, Inc.
Related Categories
Press ReleasesStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
